Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceFRA:HBI0 53 PB Ratio is 2.88 as of Aug. 24, 2026, which is 63% above its 10-year median of 1.77. GuruFocus rates FRA:HBI0 with a GF Score™ of 53/100 and a GF Value™ of €6.70. The stock has 9 warning signs investors should review. Among 781 Medical Devices & Instruments companies, Harvard Bioscience ranks worse than 77.85% on this metric.
Harvard Bioscience Inc stock PB Ratio (=4.59) is close to 10-year high of 4.59.
The historical rank and industry rank for Harvard Bioscience's PB Ratio or its related term are showing as below:
FRA:HBI0'
s PB Ratio Range Over the Past 10 Years
Min: 0.42 Med: 1.77 Max: 4.59
Current: 4.59
During the past 13 years, Harvard Bioscience's highest PB Ratio was 4.59. The lowest was 0.42. And the median was 1.77.
FRA:HBI0's PB Ratio is ranked worse than 77.85% of 781
companies
in the Medical Devices & Instruments industry
Industry Median: 2.12
vs FRA:HBI0: 4.59
During the past 12 months, Harvard Bioscience's average Book Value Per Share Growth Rate was -53.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -43.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -25.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -11.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Harvard Bioscience was 350.40% per year. The lowest was -43.60% per year. And the median was -2.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Harvard Bioscience PB Ratio Related Terms
Harvard Bioscience PB Ratio Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's PB Ratio distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Harvard Bioscience (FRA:HBI0) has a PB Ratio of 2.88 as of Aug. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Harvard Bioscience and its competitors. This is 63% above median its historical median of 1.77. Over the past decade, Harvard Bioscience's PB Ratio has ranged from 0.42 to 4.59. According to the industry distribution chart, Harvard Bioscience ranks #608 out of 781 companies in the Medical Devices & Instruments industry, placing it in the top 77.8%.
Is Harvard Bioscience's PB Ratio too high?
Harvard Bioscience's current PB Ratio of 2.88 is 63% above median its 10-year median of 1.77. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 4.59. The Medical Devices & Instruments industry median PB Ratio is 2.12. Harvard Bioscience's value of 2.88 is 35.8% above this industry median. Based on the distribution chart, Harvard Bioscience ranks #608 out of 781 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Harvard Bioscience has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's PB Ratio compare to RVP and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #608 out of 781 companies for PB Ratio. This places Harvard Bioscience in the lower half of its industry. The industry median PB Ratio is 2.12. Harvard Bioscience's value of 2.88 is 35.8% above this benchmark. Historically, Harvard Bioscience's own PB Ratio has ranged from 0.42 to 4.59 over the past decade. While the company's 10-year median is 1.77 vs. the industry median of 2.12, Harvard Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.12, based on 781 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harvard Bioscience's current PB Ratio of 2.88 is 35.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Harvard Bioscience and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current PB Ratio is 2.88, which is 63% above median its own 10-year median of 1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current PB Ratio of 2.88. The stock's GF Value™ is €6.70, compared to a current price of €4.08 — trading 39.1% below its estimated fair value. The current PB Ratio is 2.88, which is 63% above median its 10-year median of 1.77 and 35.8% above the Medical Devices & Instruments industry median of 2.12. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current PB Ratio is 2.88 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.
Key valuation signals for FRA:HBI0:
PB Ratio: 2.88 (63% above median its 10-year median of 1.77)
GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
Industry Position: 35.8% above the Medical Devices & Instruments median (#608 of 781)
No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for FRA:HBI0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HBI0 has been successfully added to your 
